Can ARVC patients exercise safely? new study aims to find out
NCT ID NCT06040242
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how different types and intensities of exercise affect heart rhythm in people with arrhythmogenic right ventricular cardiomyopathy (ARVC). Researchers will measure extra heartbeats and heart workload during activities like walking or biking. The goal is to create safe, evidence-based exercise guidelines so patients can stay active without increasing their risk of dangerous heart rhythms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2023
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
14 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Definitive ARVC diagnosis according to the modified 2010 ARVC Task Force Criteria * Pathogenic / likely pathogenic variant in one of the following desmosomal genes: plakophilin-2 (PKP-2), desmoglein-2 (DSG-2) or desmoplakin (DSP) or gene-elusive definite ARVC (i.e., genetic test performed but no pathogenic / likely pathogenic variant found) * Control group: diagnosed ischemic heart disease with ejection fraction above 35% * Agreement with responsible primary cardiologist that study participation is not considered beyond acceptable levels of physical activity for this particular patient * No history of exercise-induced syncope in the 6 months prior to study participation * No history of sudden cardiac arrest in the 6 months prior to study participation * In patients who suffered from sudden cardiac arrest/arrhythmic syncope, only those having an implantable cardioverter-defibrillator (ICD) and being under beta-blockers/antiarrhythmic drugs are eligible for study inclusion * Informed Consent as documented by signature (Appendix Informed Consent Form) * Age: \> 14 years * Body-Mass-Index (BMI): 18.5 - 39.9 kg・m-2 * Willing to adhere to the following study rules: * No intense exercise 48h prior to testing * No exercise 24h prior to testing * Sleep at least 7h the two nights before testing On test day * No caffeinated food or drink before testing on test day * No alcohol before testing on test day * Fully compliant with normal medication regimen including beta-blockers and antiarrhythmic medication Exclusion Criteria: * No genetic test history for ARVC variants * Heart failure with severely reduced left ventricular ejection fraction (LVEF \<35%) * For women: Pregnancy, breastfeeding, or intention to become pregnant during the study. * Known or suspected non-compliance, drug, or alcohol abuse * Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant * Previous enrolment into the current study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Arrhythmogenic right ventricular cardiomyopathy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Exercise Physiology Lab, Institute of Human Movement Sciences and Sport, ETH Zurich
RECRUITINGZurich, Canton of Zurich, 8092, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A glowing dye could expose hidden heart scarring
- Global registry aims to unlock clues for heart transplant success in adults born with heart defects
- Gene hunt launched for kids with heart muscle disease
- Heart inflammation clues sought in rare heart disease
- Heart disease detective: 1,000-Person study hunts for hidden genetic triggers of sudden cardiac death
- New PET scan could spot hidden heart damage in rare condition